Drug Profile


Alternative Names: Invicorp; Phentolamine/aviptadil; PSD 510; Vasopotin

Latest Information Update: 03 Apr 2015

Price : $50

At a glance

  • Originator Senetek
  • Developer Evolan Pharma; Plethora Solutions; Senetek
  • Class Gastrointestinal hormones; Imidazoles; Neuropeptides; Peptide hormones; Vasodilators
  • Mechanism of Action Alpha adrenergic receptor antagonists; Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Erectile dysfunction

Most Recent Events

  • 03 Apr 2015 Preregistration for Erectile dysfunction in United Kingdom, Germany, Sweden, Finland and Norway (Intracavernous) before April 2015
  • 25 Feb 2013 Discontinued - Phase-III for Erectile dysfunction in USA (Intracavernous)
  • 25 Feb 2013 Aviptadil/phentolamine is no longer licensed to Plethora Solutions in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top